Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lactose Tablet Clear all
Completed Phase 1Phase 2 Interventional Results available

Study of MEK162 for Children With Low-Grade Gliomas

NCT02285439
View directory record Official record
Conditions
Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms
Interventions
MEK162
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 25, 2026, 4:14 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Drugs on Responses to Brain and Emotional Processes

NCT04053036
View directory record Official record
Conditions
Autism Spectrum Disorder, Healthy
Interventions
MDMA, Placebo oral tablet
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 25, 2026, 4:14 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

NCT05249114
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Cabozantinib, Lu-177
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 25, 2026, 4:14 PM EDT
Withdrawn Phase 2 Interventional

Erlotinib for Treatment of Psoriasis

NCT01006096
View directory record Official record
Conditions
Psoriasis
Interventions
erlotinib, placebo tablet
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 25, 2026, 4:14 PM EDT
Recruiting Phase 2 Interventional

Cabozantinib for Patients With Recurrent or Progressive Meningioma

NCT05425004
View directory record Official record
Conditions
Meningioma
Interventions
Cabozantinib
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Miami, Florida • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 25, 2026, 4:14 PM EDT
Terminated Phase 2 Interventional Results available

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

NCT00302952
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lovastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 25, 2026, 4:14 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Acetazolamide Efficacy in Ataxia in PMM2-CDG

NCT04679389
View directory record Official record
Conditions
Pmm2-CDG, CDG1A
Interventions
Placebo, Acetazolamide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
4 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 25, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Urinary Track Infection Prevention After Urogynecological Surgery

NCT03818321
View directory record Official record
Conditions
Urinary Tract Infections, Urinary Retention Postoperative, Pelvic Organ Prolapse
Interventions
Methenamine Hippurate 1 g tablet, Placebo tablet
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 25, 2026, 4:14 PM EDT
Active, not recruiting Not applicable Interventional

Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)

NCT01000350
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Saline, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 4:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Treatment of Orthostatic Intolerance

NCT00262470
View directory record Official record
Conditions
Tachycardia, Chronic Orthostatic Intolerance
Interventions
Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder
Drug · Other · Dietary Supplement + 3 more
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 4:14 PM EDT
Active, not recruiting Phase 4 Interventional

Study of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis

NCT05430230
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Naproxen 500 Mg, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 25, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Results available

Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)

NCT01517711
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Tramadol, Placebo
Drug
Lead sponsor
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Other
Eligibility
21 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 25, 2026, 4:14 PM EDT
Withdrawn Phase 2 Interventional

Trial of Pancreatic Enzyme Supplements (Pancrelipase) for Treating Pain in Patients With Chronic Pancreatitis

NCT02706236
View directory record Official record
Conditions
Pancreatitis
Interventions
Pancrelipase, placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 25, 2026, 4:14 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Drug Effects on Interpersonal Interaction

NCT05123716
View directory record Official record
Conditions
Interaction, Social
Interventions
MDMA, placebo oral tablet
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 25, 2026, 4:14 PM EDT
Completed Not applicable Interventional Results available

Response to Supplement and Placebo in GERD

NCT01915173
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Heartburn, Dyspepsia
Interventions
Supplement, Placebo, Expanded Interview, Standard Interview
Drug · Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 25, 2026, 4:14 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Drugs Brain and Behavior (DDP)

NCT04642820
View directory record Official record
Conditions
Stimulant Use
Interventions
Methamphetamine, placebo oral tablet
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 25, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

NCT04401579
View directory record Official record
Conditions
COVID-19
Interventions
Placebo, Remdesivir, Baricitinib
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,033 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 25, 2026, 4:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of High Fat Meal on Cabotegravir

NCT02799264
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Cabotegravir 30 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 25, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

24-hour Mifepristone and Buccal Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation for D&E

NCT03134183
View directory record Official record
Conditions
Abortion, Second Trimester
Interventions
Vaginal Misoprostol, Buccal Misoprostol
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 25, 2026, 4:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)

NCT00950248
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
Idebenone, placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 25, 2026, 4:14 PM EDT
Active, not recruiting Not applicable Interventional

Electrical Neuromodulation for Modifying Spinal Network Involved in Spasticity

NCT07792616
View directory record Official record
Conditions
Spinal Cord Injuries (Complete and Incomplete), Spinal Cord Injury, Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injuries, Spasticity, Spasm, Muscle Spasticity, Muscle Hypertonia, Muscle Spasm
Interventions
Transcutaneous spinal stimulation at 30 Hz, Transcutaneous spinal stimulation at 75 Hz, Tizanidine, Baclofen, Placebo
Other · Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 25, 2026, 4:14 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

NCT02951052
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), 2 NRTIs plus an INI, NNRTI, or PI
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 25, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite

NCT04996264
View directory record Official record
Conditions
Snakebites, Envenoming, Envenoming, Snake, Envenomation, Snake
Interventions
Varespladib Methyl, Placebo, Standard of care (SOC)
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
5 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Tucson, Arizona • Loma Linda, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 25, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy

NCT00283816
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Oral Contraceptive Pill, Lifestyle Management Program, Quality of Life Questionnaire, Oral Glucose Tolerance Test, Blood work, Abdominal Ultra Sound, Dual-energy x-ray absorptiometry (DEXA scan), placebo
Drug · Behavioral · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 25, 2026, 4:14 PM EDT